Our findings are consistent with the inefficacy of B-cell deletion to modulate the disease burden and survival of mutant SOD1 ALS mice (50), despite the appearance of autoantibodies in this model. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.